EVEREST MED (01952) saw its shares rise more than 5% during the morning trading session. At the time of writing, the stock was up 4.75%, trading at HK$35.7, with a turnover of HK$44.2498 million. The movement follows a recent company announcement regarding a key development in the patent protection of its innovative product, budesonide enteric-coated capsules (Nefecon). The Guangzhou Intellectual Property Court issued a civil ruling on February 26, 2026, fully supporting the company's application for pre-litigation behavioral preservation. The court ordered relevant generic drug manufacturers to immediately cease infringing activities and withdraw their products from listing platforms, with the ruling taking effect immediately. It was reported that in December 2025, Hainan Herui Pharmaceutical's generic version of budesonide enteric-coated capsules became the first to receive approval for market entry.